Navigation Links
Real Time Genomics Launches Two New Products in Human Disease Research

San Francisco, California (PRWEB) August 27, 2013

Real Time Genomics, Inc., the genome analytics company, today announced the commercial introduction of its rtgSingleton™ product for the genomic analysis of individual samples, and the Beta release of its rtgPopulation™ product for case-control and cohort applications. The singleton product is designed to analyze panels, exomes or genomes on a case-by-case basis. The population product is designed to work under two distinct scenarios: (1) analyze large sample numbers simultaneously; and (2) leverage prior information obtained from a population dataset to improve outcomes in the analysis of population subsets. The two new products complement the company’s rtgFamily™ offering, which is the industry leader in genomic analysis for early childhood disease.

The company also announced an exciting new milestone for its pedigree-aware rtgFamily product. RTG’s R&D team has validated that the product can reduce the cost of sequencing trios (both parents and a child) by at least 33 percent with no tradeoff in accuracy by enabling the parents of an offspring to be sequenced at half the typical coverage and still identify recessive, compound heterozygotes, and autosomal dominant disease variants. Results from this reduced-sequencing workflow showed greater than 99.9 percent concordance between variants identified in the proband when compared to sequencing the trio at full-coverage. In addition, the reduced coverage workflow maintained RTG’s sixty-fold reduction in Mendelian inconsistent errors for the proband as compared to analyzing that individual without parental genomes. To expand this validation across a wide array of samples, the company kicked off the ‘3-for-2 Challenge’ whereby a limited number of customers can submit trio data to RTG to be analyzed at both full and reduced-parental coverage. Results will be delivered free of charge directly to customers at this year’s ASHG conference in Boston, MA. Details about the cost reduction capabilities of rtgFamily and the ‘3-for-2 Challenge’ can be found on the company’s website.

“The ability to deliver improved results at a fraction of the cost could advance early childhood disease outcomes by enabling more family sequencing,” said Jason Blue-Smith, Head of Product for Real Time Genomics. “Capitalizing on the accuracy benefits of using parental genotypes, medical researchers have now successfully integrated our pedigree-aware product into their clinical workflows. The addition of singleton and population products to RTG’s human genetics portfolio allows biomedical researchers to run different experiment types through a uniform core analytical technology.”

About Real Time Genomics, Inc.
Real Time Genomics ( has a passion for genomics. The company offers software tools and applications for the extraction of unique value from genomic data. Its competency lies in applying the combination of its patented core technology and deep computational expertise in algorithms to solve problems in next generation genomic analysis. Real Time Genomics is a private San Francisco based company backed by investment from Catamount Ventures, Lightspeed Venture Partners, and GeneValue Ltd.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program
2. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
3. Rubicon Genomics and Agendia Sign Agreement for Use of TransPLEX® Whole Genome RNA Amplification Technology With Symphony™ Cancer Diagnostics
4. Synthetic Genomics Inc. Purchases 81 Acre Site in South California Desert for Scale up and Testing of Innovative Algae Strains
5. Rosetta Genomics Pays Off Secured Loan and Reclaims Unencumbered Rights to All Assets
6. First Plant Genomics Yield Technology Progresses
7. Rosetta Genomics Announces Closing of Public Offering of 5.5 Million Ordinary Shares
8. Rosetta Genomics Receives 2012 North American Entrepreneurial Company of the Year Award by Frost & Sullivan
9. Rosetta Genomics Expands Management Team, Laboratory Capacities and Commercial Operations
10. Epigenomics, Present and Future Applications for Pharmaceuticals and Diagnostics:
11. Synthetic Genomics Inc. Purchases Patent Portfolio from Febit Holding GmbH
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... The Academy of Model ... Group (SIG), MultiGP, also known as Multirotor Grand Prix, to represent the First–Person View ... years. Many AMA members have embraced this type of racing and several new model ...
(Date:11/24/2015)... Israel , Nov. 24, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) ... on December 29, 2015 at 11:00 a.m. Israel ... Electra Tower, 98 Yigal Allon Street, 36 th Floor, ... of Eric Paneth and Izhak Tamir to the ... Rami Skaliter as external directors; , approval of an amendment to ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... the environment are paramount. Insertion points for in-line sensors can represent a weak ... the InTrac 781/784 series of retractable sensor housings , which are designed ...
(Date:11/24/2015)... Nov. 24, 2015 /CNW Telbec/ - ProMetic Life Sciences Inc. ... that Mr. Pierre Laurin , President and Chief Executive ... the upcoming Piper Jaffray 27 th Annual Healthcare Conference ... December 1-2, 2015. st , at 8.50am ... meetings throughout the day. The presentation will be available live ...
Breaking Biology Technology:
(Date:11/9/2015)... , Nov. 9, 2015  Synaptics Inc. (NASDAQ: ... today announced broader entry into the automotive market with ... match the pace of consumer electronics human interface innovation. ... are ideal for the automotive industry and will be ... Europe , Japan ...
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has been ... provide preclinical development services to the National Cancer Institute ... will provide scientific expertise, modern testing and support facilities, ... preclinical pharmacology and toxicology studies to evaluate potential cancer ... The PREVENT Cancer Drug Development Program is an ...
(Date:10/29/2015)... Calif. , Oct. 29, 2015  The J. ... new report titled, "DNA Synthesis and Biosecurity: Lessons Learned ... the Department of Health and Human Services guidance for ... in 2010. --> ... it also has the potential to pose unique biosecurity ...
Breaking Biology News(10 mins):